DTR-Pseudomonas aeruginosa: Applying Best Practices in Complex Clinical Scenarios

In this episode, Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections involving Pseudomonas aeruginosa with difficult-to-treat resistance, including: 

• Mechanisms of β-lactam resistance
• Effect of resistance mechanism on susceptibility to antipseudomonal agent
• 2023 IDSA guidance recommendations 
• Activity against newer antipseudomonal β-lactams in the United States
• The latest clinical data by antimicrobial regimen:

              - Ceftolozane/tazobactam
              - Ceftazidime/avibactam
              - Imipenem/cilastatin/relebactam
              - Cefiderocol

• Applying antimicrobial stewardship principles

Program Director:

Trevor Van Schooneveld, MD, FSHEA, FACP  
Professor, Division of Infectious Diseases
Program Director, Infectious Diseases Fellowship
Medical Director, Antimicrobial Stewardship Program
University of Nebraska Medical Center
Omaha, Nebraska

Faculty:

Emily Heil, PharmD, MS, BCIDP, AAHIVP
Associate Professor
Department of Pharmacy
University of Maryland  
School of Pharmacy
ID Clinical Pharmacy Specialist
University of Maryland Medical Center|
Baltimore, Maryland

Laila Woc-Colburn, MD
Associate Professor
Division of Infectious Diseases
Emory University School of Medicine  
Atlanta, Georgia

Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Follow along with a downloadable slideset at: https://clinicaloptions.com/CE-CME/infectious-disease/cmv-prevention-in-sot-recipients/26139

Link to full program: https://bit.ly/40HyvPy

 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.